STAT

They got hundreds of thousands to rally. Where does the March for Science go from here?

The rally was a demonstration of enthusiasm and political clout. But organizers now hope to turn a march into a movement.
People carry a March for Science banner and signs as they pass the Environmental Protection Agency during the March For Science in Washington in April.

WASHINGTON — The hundreds of thousands of people who rallied on the National Mall and in cities worldwide for the March for Science in April came to be noticed. It was a march meant to demonstrate enthusiasm and political clout, and by those measures, organizers believe they succeeded.

But as two dozen of them met in New York the following month for a debrief, they faced an obvious reality: A grass-roots organization that was quickly formed to plan a singular event was not, at least immediately, equipped for far-reaching and long-term science advocacy.

“The big picture question was (and continues to be): How do we successfully transition from a march into a movement and how do we continue to mobilize our diverse, interdisciplinary, passionate supporters for

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related